OMVYENCE 100 MG — DIN 02510308
INFLIXIMAB : 100 MG · JANSSEN INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: APPROVED
What is OMVYENCE?
OMVYENCE 100 MG contains INFLIXIMAB : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02510308, held by JANSSEN INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 29-Dec-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
How much does Infliximab cost around the world?
Infliximab is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 6 | 295 | AUD███.██ |
| Hungary | producer price (ex-factory) | 7 | 19 | HUF███.██ |
| United Arab Emirates | public | 6 | 10 | AED███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 10 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 4 | 10 | CZK███.██ |
| Bahrain | retail (max) | 4 | 9 | BHD███.██ |
| Romania | max producer price | 6 | 9 | RON███.██ |
| Italy | ex-factory (classe H) | 8 | 8 | EUR███.██ |
| Saudi Arabia | public | 7 | 8 | SAR███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| Iceland | max wholesale | 4 | 5 | ISK███.██ |
| Slovakia | categorised final price | 5 | 5 | EUR███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
| South Africa | single exit price | 3 | 3 | ZAR███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
403 pack listings across 76 brand entries and 13 price bases, refreshed 08 Sep 2026. Ranges span every Infliximab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Infliximab in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Infliximab, across 9 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| CELLTRION INC. | 4 | 2 | REMDANTRY, REMSIMA, REMSIMA SC | Sourceable in Canada |
| JANSSEN INC | 2 | 1 | OMVYENCE, REMICADE | Sourceable in Canada |
| AMGEN CANADA INC | 1 | 1 | AVSOLA | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | IXIFI | Sourceable in Canada |
| SAMSUNG BIOEPIS CO., LTD | 1 | 1 | RENFLEXIS | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Infliximab |
|---|---|
| ATC code | L04AB02 |
| AHFS class | 90:24.16.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02510308 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2510308 |
| Brand name | OMVYENCE |
| Generic / active ingredient | INFLIXIMAB : 100 MG |
| Market authorization holder | JANSSEN INC |
| Health Canada schedule | Schedule D |
| ATC code | L04AB02 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04AB |
| Current status | APPROVED |
| Status date | 29-Dec-2020 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AVSOLA | 100 MG | POWDER FOR SOLUTION | AMGEN CANADA INC | MARKETED | 02496933 |
| IXIFI | 100 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02523191 |
| REMDANTRY | 100 MG | POWDER FOR SOLUTION | CELLTRION INC. | MARKETED | 02419475 |
| REMICADE | 100 MG | POWDER FOR SOLUTION | JANSSEN INC | MARKETED | 02244016 |
| REMSIMA SC | 120 MG | SOLUTION ; KIT | CELLTRION INC. | MARKETED | 02511584 |
| RENFLEXIS | 100 MG | POWDER FOR SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | 02470373 |
| REMSIMA | 100 MG | POWDER FOR SOLUTION | CELLTRION INC. | CANCELLED POST MARKET | 02419483 |
| REMSIMA SC | 120 MG | KIT ; SOLUTION | CELLTRION INC. | APPROVED | 02511576 |
2 · Same class — other molecules in ATC L04AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Adalimumab | ABRILADA · AMGEVITA · HADLIMA · HADLIMA PUSHTOUCH · +6 more | 41 | 34 | Yes |
| Etanercept | BRENZYS · ENBREL · ERELZI · RYMTI | 10 | 8 | Yes |
| Infliximab | AVSOLA · IXIFI · OMVYENCE · REMDANTRY · +4 more | 9 | 6 | Yes |
| Golimumab | LIVMOTY · SIMPONI · SIMPONI I.V. | 9 | 5 | Yes |
| Certolizumab Pegol | CIMZIA | 2 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L04AX | Azathioprine · Dimethyl Fumarate · Lenalidomide · Methotrexate · Other Immunosuppressants · +3 more | 191 | 124 |
| L04AC | Anakinra · Basiliximab · Bimekizumab · Brodalumab · Canakinumab · +13 more | 85 | 75 |
| L04AA | Abatacept · Alefacept · Antilymphocyte Immunoglobulin (Horse) · Antithymocyte Immunoglobulin (Rabbit) · Apremilast · +4 more | 73 | 42 |
| L04AD | Ciclosporin · Tacrolimus | 49 | 30 |
| L04AK | Leflunomide · Teriflunomide | 44 | 25 |
| L04AH | Everolimus · Sirolimus | 36 | 23 |
| L04AF | Baricitinib · Deucravacitinib · Ritlecitinib · Tofacitinib · Upadacitinib | 23 | 19 |
| L04AG | Alemtuzumab · Anifrolumab · Belimumab · Efalizumab · Inebilizumab · +7 more | 20 | 15 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is OMVYENCE called?
The same molecule, Infliximab, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Remsima | Latin | Australia, Bahrain, Czechia, Iceland |
| Ixifi | Latin | Australia, Bahrain, Saudi Arabia |
| Renflexis | Latin | Australia, Saudi Arabia |
| Inflectra | Latin | Australia |
| Remsima SC | Latin | Australia, Bahrain, Saudi Arabia |
| Remicade | Latin | Australia, Bahrain, Czechia, Iceland, Morocco, United Arab Emirates |
| Flixabi | Latin | Czechia, Iceland |
| Zessly | Latin | Czechia, Iceland |
| Remiflix | Latin | South Africa |
| Revellex | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.